Meropenem

C difficile risk
Medium
Oral Bioavailability
N/A
Cost
$15/day

Dosing

Defined criteria for use and/or important safety considerations. See below for more information.

500 mg IV q6h

2 g IV q8h

CrCl > 50 mL/minCrCl 30 - 50 mL/minCrCl 10 - 30 mL/minCrCl < 10 mL/minNo renal adjustment required500 mg IV q8h500 mg IV q12h500 mg IV q24h

CrCl > 50 mL/minCrCl 30 - 50 mL/minCrCl 10 - 30 mL/minCrCl < 10 mL/minNo renal adjustment required2 g IV q12h1 g IV q12h1 g IV q24h

Most IndicationsCNS Infections, Cystic Fibrosis, and Endophthalmitis500 mg IV q24h

  • Give dose after dialysis on HD days1 g IV q24h

  • Give dose after dialysis on HD days

Most IndicationsCNS Infections, Cystic Fibrosis, and Endophthalmitis500 mg IV q24h1 g IV q24h

Most IndicationsCNS Infections, Cystic Fibrosis, and Endophthalmitis1 g IV q8h2 g IV q12h

General Information

  • Treatment of documented or suspected infections resistant to piperacillin-tazobactam or third-generation cephalosporins

  • Infections with ESBL or, AMP-C producing bacteria

  • Stenotrophomonas, MRSA, Enterococcus or VRE

  • Atypical infections like Legionella

Valproic acid - Carbapenems decrease valproate levels and may decrease seizure threshold

Antimicrobial class: Carbapenem

Pregnancy category: B

Average serum half life: 1 hour

Urine penetration: Therapeutic

Lung penetration: Therapeutic

CSF penetration: Therapeutic (with higher doses)

Biliary penetration: Therapeutic

Terms of Use | Feedback
© Copyright 2021 Spectrum Mobile Health Inc., dba Firstline Clinical. All rights reserved.